AC
ESLA icon

Armistice Capital’s Estrella Immunopharma ESLA Stock Holding History

Armistice Capital’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Sell
3,975,220
-123,780
-3% -$162K 0.05% 139
2026
Q1 		$4.34M Buy
+4,099,000
New +$4.71M 0.08% 128

Other funds holding ESLA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's ESLA Position: Q2 2026 in Review

Armistice Capital reduced its Estrella Immunopharma (ESLA) stake by 3% in Q2 2026, selling an estimated $162K and leaving 3,975,220 shares worth $4.13M. The position accounts for 0.05% of the portfolio, ranked #139.

Armistice Capital first reported a position in ESLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.34M in Q1 2026. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Armistice Capital held 3,975,220 shares of Estrella Immunopharma worth $4.13M as of Q2 2026.
  • Armistice Capital sold 123,780 Estrella Immunopharma shares in Q2 2026, an estimated $162K.
  • Estrella Immunopharma made up 0.05% of Armistice Capital's portfolio in Q2 2026, its #139 holding.
  • Armistice Capital first reported a position in Estrella Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • Armistice Capital's Estrella Immunopharma position peaked at $4.34M in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.